Methylene Blue Emerges as a Promising Rescue Drug for Refractory Shock in the ICU
A 2025 review examines how methylene blue's nitric oxide inhibition can restore vascular tone in septic and vasoplegic shock patients.
Summary
Methylene blue (MB), long used as a dye and antiseptic, is gaining traction in critical care as a vasopressor-sparing agent for refractory shock. By blocking nitric oxide synthase and soluble guanylate cyclase, MB reverses the catastrophic vasodilation seen in septic and vasoplegic shock. This narrative review of PubMed and Google Scholar literature synthesizes evidence from RCTs, prospective studies, and meta-analyses showing MB increases mean arterial pressure, reduces vasopressor requirements, lowers lactate levels, and may decrease mortality. Documented effective dosing ranges from 0.25–2 mg/kg/hour as continuous infusion. Early administration — within roughly 8 hours of sepsis onset, or while still in the operating room for cardiac surgery — yields better outcomes than late rescue use. Side effects at therapeutic doses are minimal, with blue-green urine discoloration being the most common.
Detailed Summary
Methylene blue (MB) has been used in medicine for over a century, primarily for methemoglobinemia and as a biological dye, but a growing body of critical care literature is repositioning it as a meaningful adjunct therapy for distributive and vasoplegic shock. This 2025 narrative review, published in the World Journal of Critical Care Medicine, synthesizes evidence from PubMed and Google Scholar across RCTs, prospective studies, retrospective cohorts, and meta-analyses to characterize MB's mechanisms, optimal dosing, clinical indications, and safety profile in the ICU.
MB's primary mechanism in shock involves dual inhibition of endothelial and inducible nitric oxide synthase, as well as downstream blockade of soluble guanylate cyclase. This interrupts the NO–cGMP pathway that drives pathological vasodilation in sepsis and vasoplegic syndrome, restoring vascular smooth muscle tone and increasing systemic vascular resistance. MB also scavenges free NO directly and — separately — acts as an electron donor that converts methemoglobin back to functional hemoglobin, explaining its established role in methemoglobinemia. Its terminal half-life of approximately 5.25 hours necessitates repeated boluses or continuous infusion for sustained effect.
For septic shock, a systematic review by Ng et al found 5 RCTs using MB at 2 mg/kg, demonstrating increased MAP, reduced vasopressor requirements, and improved PaO2/FiO2 ratios, with reductions in mortality, serum lactate, and hospital length of stay. A larger meta-analysis by Zhao et al (10 RCTs and 5 observational studies, n=832) found MB significantly decreased mortality (OR=0.54, 95%CI: 0.34–0.85, P=0.008) and vasopressor dose (MD: −0.77, 95%CI: −1.26 to −0.28, P=0.002), while also increasing MAP, heart rate, SVR, and reducing lactate and incidence of renal failure. Alkazemi et al's analysis of 5 RCTs and 10 non-RCTs similarly confirmed mortality reductions in both overall and RCT-only subgroup analyses.
In vasoplegic syndrome following cardiopulmonary bypass, evidence strongly favors early intraoperative MB administration over postoperative ICU rescue use. Mehaffey et al's retrospective study found early MB reduced risk-adjusted major adverse events (OR=0.35, P=0.037) and improved survival. Ozal et al's prospective study showed pre-operative MB (2 mg/kg) reduced vasoplegic syndrome incidence from 26% to 0% (P<0.001) and shortened both ICU and hospital stays. A recent 2025 RCT by Shaker et al compared 1 mg/kg vs 4 mg/kg bolus doses followed by 0.25 mg/kg/hour infusion for 72 hours; the higher 4 mg/kg dose was associated with a hazard ratio of 0.29 for mortality protection and shorter time to vasopressor termination. MB has also shown benefit in obstructive jaundice surgery, liver transplantation reperfusion syndrome, anaphylactic shock, and — in animal models — hemorrhagic shock, where MB combined with blood transfusion produced significantly higher MAP recovery than transfusion alone (P<0.05).
Safety at therapeutic doses appears favorable. Continuous 48-hour infusions have been administered without significant adverse events beyond blue-green urine and transient skin discoloration. Doses exceeding 7 mg/kg, however, carry the risk of compromised splanchnic perfusion. The review also compares MB to hydroxocobalamin for post-bypass vasoplegic shock; a 2024 meta-analysis by Cadd et al (4 retrospective studies, n=263) found hydroxocobalamin produced greater MAP improvement at 1 hour (MD: +5.30 mmHg) and greater vasopressor dose reductions at 1 and 6 hours, though no mortality difference was observed between agents. A key gap remains: there are no large, well-powered RCTs establishing definitive protocols for MB dose, initiation timing, and treatment duration. Heterogeneity across existing studies and small sample sizes limit the strength of current conclusions.
Key Findings
- Meta-analysis of 10 RCTs + 5 observational studies (n=832) found MB reduced mortality (OR=0.54, 95%CI: 0.34–0.85, P=0.008) and vasopressor requirements (MD: −0.77, P=0.002) vs control
- Early MB in cardiac surgery (intraoperative) reduced major adverse events vs postoperative ICU administration (OR=0.35, P=0.037) including lower renal failure and operative mortality
- 4 mg/kg bolus MB dose yielded a hazard ratio of 0.29 for mortality protection vs 1 mg/kg bolus, with faster vasopressor discontinuation in a 2025 RCT
- Preoperative MB (2 mg/kg) eliminated vasoplegic syndrome incidence in coronary bypass surgery (0% vs 26%, P<0.001) and shortened ICU and hospital stays
- MB reduced ICU length of stay (MD: −1.54 days, 95%CI: −2.61 to −0.48) and hospital LOS (MD: −1.97 days) and mechanical ventilation duration (MD: −0.68 days) across 6 RCTs
- Hydroxocobalamin outperformed MB for post-bypass vasoplegia at 1 hour MAP improvement (MD: +5.30 mmHg, 95%CI: 2.98–7.62) and vasopressor reduction, though mortality was equivalent
- Doses >7 mg/kg compromise splanchnic perfusion; therapeutic doses (0.25–2 mg/kg/hour infusion) produced only benign blue-green urine discoloration in 48-hour continuous infusion studies
Methodology
This is a narrative minireview synthesizing PubMed and Google Scholar literature using search terms including 'methylene blue,' 'critical care,' 'intensive care,' 'sepsis,' 'surgery,' 'pharmacokinetics,' and 'pharmacodynamics,' restricted to English-language publications. The review incorporates RCTs, prospective and retrospective observational studies, meta-analyses, and animal studies without formal quality scoring or PRISMA methodology. Source studies ranged widely in sample size (as small as single-center cohorts to n=832 pooled), limiting statistical heterogeneity assessment. No independent meta-analysis or pooled statistical modeling was performed by the review authors.
Study Limitations
The review is a narrative synthesis without formal systematic review methodology, making it vulnerable to selection bias and unable to formally assess publication bias or heterogeneity across included studies. Most individual trials have small sample sizes, and significant heterogeneity exists in MB dosing protocols, timing of administration, patient populations, and outcome definitions across studies. No conflicts of interest are declared by the authors, but the absence of large multicenter RCTs means current evidence is insufficient to establish standardized clinical protocols.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.